Novel dose–response analyses of treprostinil in pulmonary arterial hypertension and its effects on six-minute walk distance and hospitalizations

Treprostinil is a prostacyclin analogue approved for the treatment of pulmonary arterial hypertension. Apart from the inhaled formulation, there is neither a target dose nor a ceiling dose to guide clinicians using treprostinil; doses are individualized for each patient based upon tolerability and c...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramani, Gautam, Cassady, Steven, Shen, Eric, Broderick, Meredith, Wasik, Allie, Sui, Qun, Nelsen, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8826281/
https://www.ncbi.nlm.nih.gov/pubmed/35154662
http://dx.doi.org/10.1177/2045894020923956

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8826281/
https://www.ncbi.nlm.nih.gov/pubmed/35154662
http://dx.doi.org/10.1177/2045894020923956

Ejemplares similares